Ref: RDFR20200122001 – Una empresa francesa que desarrolla un nuevo enfoque de terapias enzimáticas para la enfermedad lisosómica está buscando socios con enfoques complementarios

El plazo para presentar expresiones de interés finaliza el 11/02/2020
La fecha límite de la convocatoria es 18/02/2020
Description: A French start-up created in 2012 develops new therapeutic approach based on membrane receptor targeting and nanomaterials. The technology allows the targeting of drugs to lysosomes for therapies of lysosomal storage diseases or cancer.
The company would like to establish new partnerships to develop lysosomal disease treatments combining enzyme replacement therapy with other therapeutics (gene therapy, chaperone,…) in order to make a joint proposal for EJP RD JTC2020 call for project.
Solicite mayor información mencionando el código de referencia.